CAF
Morgan Stanley China A Share Fund, Inc.
Set alert
- YTD
- -9.91%
- 1 year
- -9.12%
- Open
- 15.73
- Prev close
- 15.90
- Mkt cap
- 208.86M
- Vol
- 6.98K
- Avg vol
- 12.54K
- EPS
- 9.16
- P/E
- 1.71
- Div yield
- 0.02%
More statistics
- Low
- 15.62
- High
- 15.83
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.46
- Inst. own
- 85.06%
- Dividend
- 0.00
- Ex-div date
- Dec 14, 2022
- 50-d avg
- 12.87
- 200-d avg
- 12.25
- 1y target
- 0.00
Discussion (1)
Sign in to join the discussion
VICKY HANUKA CAF 3 years ago #1$PTC Therapeutics(PTCT.US)$ ?????????????? Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics' Royalty on Evrysdi -- Royalty Pharma purchases a portion of royalties on Roche's Evrysdi for
$1.0 billion upfront
-- PTC Therapeutics has option to sell rest of royalty for up to $500
million; Royalty Pharma has option to buy half of rest of royalty for up
to $250 million
-- Transaction expected to enhance long-term Adjusted Cash Receipts growth
(non-GAAP)
-- Royalty Pharma to host conference call today, Thursday, October 19 at
9:00am EDT
NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. to acquire additional royalties on Roche's Evrysdi for $1.0 billion upfront. The agreement includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to $500 million or for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date.